Clinical Trials Logo
  1. Home
  2. Non-Alcoholic Steatohepatitis
  3. NCT02721264

Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.

Non Alcoholic Steatohepatitis Clinical Trial

Official title:
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis: A Randomized Control Trial

Clinical Trial Summary

Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who meet the inclusion criteria and who provide informed consent will be included in the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02721264
Study type Interventional
Source Institute of Liver and Biliary Sciences, India
Contact Dr Abhinav Verma, MD
Phone 011-46300000
Email abhinav.3183@gmail.com
Status Recruiting
Phase N/A
Start date March 1, 2016
Completion date June 30, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Completed NCT01695083 - Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Not yet recruiting NCT05605158 - Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01761370 - Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) N/A
Completed NCT03432377 - Coffee Consumption and NASH in the French Population.
Withdrawn NCT03864835 - NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal N/A
Completed NCT05357352 - Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Not yet recruiting NCT03803540 - Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis Phase 1
Completed NCT02395900 - The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Phase 2/Phase 3
Completed NCT01791959 - The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Phase 2/Phase 3
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT03734510 - The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study N/A
Terminated NCT03883607 - Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT03863574 - Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT03377153 - The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT03377140 - The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT04669158 - Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Phase 1/Phase 2
Recruiting NCT06176079 - Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
Withdrawn NCT01384578 - Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis Phase 3